The uterine fibroids treatment market size is expected to see strong growth in the next few years. It will grow to $6.46 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in non-invasive treatment, increasing emphasis on fertility preservation, rise in minimally invasive techniques, personalized medicine approaches, collaborative research and development. Major trends in the forecast period include rising focus on fertility-preserving treatments, integration of imaging technologies in treatment planning, increasing awareness and education initiatives, customized treatment plans based on patient profiles, exploration of novel therapeutic targets.
The anticipated growth in the uterine fibroids treatment market is attributed to the high prevalence of uterine fibroids among women. Uterine fibroids, non-cancerous growths in the uterus, can lead to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel. Uterine fibroids treatment involves blocking estrogen and progesterone production, ceasing menstruation, and improving anemia. For example, a November 2022 report from the National Centre for Biotechnology Information revealed an estimated incidence of uterine fibroids ranging from 40 to 60% among women under 35 and 70 to 80% among women over 50. Thus, the widespread prevalence of uterine fibroids worldwide propels the uterine fibroids treatment market's growth.
The expected rise in healthcare expenditure is set to drive the uterine fibroids treatment market. Healthcare expenditure denotes the total financial resources allocated by a country, government, organization, or individual for healthcare-related goods and services within a specific timeframe. Increased healthcare expenditure supports the development and adoption of advanced uterine fibroids treatment options, including minimally invasive procedures such as uterine artery embolization or magnetic resonance-guided focused ultrasound surgery. For instance, in 2022, Poland's healthcare expenditure reached PLN 205.6 billion ($50.99 billion), representing 6.7% of GDP, a growth of about PLN 36.1 billion ($8.95 billion) from 2021. Hence, the escalating healthcare expenditure contributes to the uterine fibroids treatment market's expansion.
Product innovations are emerging as a significant trend in the uterine fibroid treatment market. Companies in this sector are implementing innovative solutions to maintain their competitive edge. For example, in September 2024, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched YSELTY, a new treatment for uterine fibroids that represents a major advancement in women's healthcare. YSELTY provides a non-hormonal treatment option with flexible dosing tailored to individual patient needs, especially for those experiencing severe fibroid symptoms. As a GnRH receptor antagonist, YSELTY works by inhibiting gonadotropin-releasing hormone at its pituitary receptors, thereby reducing estrogen production and effectively alleviating symptoms like bleeding and pain.
Significant players in the uterine fibroids treatment market are directing their efforts toward developing minimally invasive procedures (MIPs) for addressing uterine fibroids. Minimally invasive procedures involve medical interventions or surgeries that cause minimal disruption to the body's normal structure and function. These procedures aim to alleviate symptoms such as heavy menstrual bleeding and pelvic pain while reducing recovery times and preserving reproductive options. As an illustration, Humber River Hospital in Canada launched the use of the Acessa ProVu system in November 2022. This medical technology employs monopolar radiofrequency (RF) energy through a disposable Handpiece for percutaneous, laparoscopic coagulation, and ablation of soft tissue, including the treatment of symptomatic uterine fibroids.
In January 2022, Hologic Inc., a US-based medical technology company, acquired Acessa Health for $80 million, enhancing Hologic’s presence in the gynecological surgical space. Acessa Health, a US-based biotechnology company, specializes in developing minimally invasive, uterine-sparing devices designed to treat women suffering from symptomatic fibroids.
Major companies operating in the uterine fibroids treatment market include Gynesonics Inc., Medtronic plc, Boston Scientific Corporation, Karl Storz GmbH, Pfizer Inc., Abbvie Inc., Richard Wolf GmbH, CooperSurgical Inc., Olympus Corporation, Myovant Sciences GmbH, Insightec Ltd., Hologic Inc., Obseva SA, Eli Lilly and Company, GlaxoSmithKline plc, Stryker Corporation, Smith & Nephew plc, Minerva Surgical Inc., Ethicon Inc., Cook Medical LLC, C.R. Bard Inc., Biomerics LLC, Visionsense Corp., Halt Medical Inc., Acessa Health Inc., Blue Endo, LiNA Medical ApS, Merit Medical Systems Inc., Allergan plc, Astellas Pharma Inc.
North America was the largest region in the uterine fibroids treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uterine fibroids treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Uterine fibroids treatment encompasses procedures aimed at addressing uterine fibroids, which are non-cancerous growths that form in the uterus, potentially leading to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel.
The primary categories of uterine fibroids treatment consist of subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids. Subserosal fibroids, also known as pedunculated fibroids, are benign growths located on the outer uterine wall, directly connected to the uterus. Various treatment options are available, including hormone therapy, androgens, gonadotropin-releasing hormone antagonists, uterine artery embolization, myomectomy, and hysterectomy. These treatments cater to diverse end-users such as hospitals, ambulatory surgical centers, and others.
The uterine fibroid treatment market research report is one of a series of new reports that provides uterine fibroid treatment market statistics, including uterine fibroid treatment industry global market size, regional shares, competitors with a uterine fibroid treatment market share, detailed uterine fibroid treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid treatment industry. This uterine fibroid treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The uterine fibroids treatment market includes revenues earned by entities by providing medical, surgical, and radiologically guided therapies available as treatments for uterine fibroids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Uterine Fibroids Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on uterine fibroids treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for uterine fibroids treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uterine fibroids treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Subserosal Fibroids; Intramural Fibroids; Submucosal Fibroids; Pedunculated Fibroids2) By Treatment Type: Hormone Therapy; Androgens; Gonadotropin-Releasing Hormone Antagonists; Uterine Artery Embolization; Myomectomy; Hysterectomy
3) By End-Users: Hospitals; Ambulatory Surgical Centers; Other End users
Subsegments:
1) By Subserosal Fibroids: Pedunculated Subserosal Fibroids; Non-Pedunculated Subserosal Fibroids2) By Intramural Fibroids: Small Intramural Fibroids; Large Intramural Fibroids
3) By Submucosal Fibroids: Pedunculated Submucosal Fibroids; Non-Pedunculated Submucosal Fibroids
4) By Pedunculated Fibroids: Subserosal Pedunculated Fibroids; Submucosal Pedunculated Fibroids
Key Companies Mentioned: Gynesonics Inc.; Medtronic plc; Boston Scientific Corporation; Karl Storz GmbH; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Gynesonics Inc.
- Medtronic plc
- Boston Scientific Corporation
- Karl Storz GmbH
- Pfizer Inc.
- Abbvie Inc.
- Richard Wolf GmbH
- CooperSurgical Inc.
- Olympus Corporation
- Myovant Sciences GmbH
- Insightec Ltd.
- Hologic Inc.
- Obseva SA
- Eli Lilly and Company
- GlaxoSmithKline plc
- Stryker Corporation
- Smith & Nephew plc
- Minerva Surgical Inc.
- Ethicon Inc.
- Cook Medical LLC
- C.R. Bard Inc.
- Biomerics LLC
- Visionsense Corp.
- Halt Medical Inc.
- Acessa Health Inc.
- Blue Endo
- LiNA Medical ApS
- Merit Medical Systems Inc.
- Allergan plc
- Astellas Pharma Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | February 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 4.44 Billion |
Forecasted Market Value ( USD | $ 6.46 Billion |
Compound Annual Growth Rate | 9.8% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |